EBS News & Events

Emergent BioSolutions announced it has been awarded a contract modification valued at approximately $64.5M from the Administration for Strategic Preparedness and Response, or ASPR, a division of the United States Department of Health and Human Services, or HHS, for Botulism Antitoxin Heptavalent. The modification has been made to the existing 10-year contract with ASPR whereby Emergent will supply BAT, an antitoxin used in the treatment of symptomatic botulism following suspected or confirmed exposure to botulinum neurotoxin serotypes in both adults and pediatric patients.

Emergent BioSolutions announced that the Saudi Food and Drug Authority has approved the registration of ACAM2000 for the prevention of smallpox and mpox disease in individuals determined to be at high risk for infection. "We are pleased to receive this approval for ACAM2000 from SFDA for immunization against smallpox and mpox in high-risk individuals," said Simon Lowry, chief medical officer of Emergent. "ACAM2000 is the first Emergent product to be licensed by the SFDA and demonstrates the company's intent to collaborate with governments in the Gulf region and around the world as awareness and adoption of biodefense preparedness strategies continues to increase around the world."

Emergent BioSolutions announced that Singapore's Health Sciences Authority has approved an expanded indication for ACAM2000 to include prevention of mpox disease in adults determined to be at high risk for mpox infection. "The Singapore HSA approval of ACAM2000 for immunization against mpox in high-risk individuals demonstrates the strength and breadth of Emergent's medical countermeasures portfolio," said Simon Lowry, chief medical officer of Emergent. "We are committed to working with international regulatory authorities as part of our broader vision to become the leader in delivering protective and life-saving solutions to communities around the world."

Emergent BioSolutions (EBS) announced a multi-year agreement with SAB Biotherapeutics (SABS) to support the process development and manufacturing of SAB-142, SAB BIO's lead program in clinical development for autoimmune type 1 diabetes. The executed agreement is valued at approximately $50M, of which $36M is contingent on future regulatory approval and downstream milestones. Under the terms of the agreement, Emergent will provide end-to-end development and manufacturing services to SAB BIO that are compliant with current good manufacturing practices. These services will include process development and scale-up, technology and analytical method transfer, manufacturing for SAB-142's ongoing clinical program and commercial manufacturing services upon regulatory approval.